{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/fr\/","title":"Progr\u00e8s de la mise au point d\u2019un agent neutralisant les effets des nouveaux anticoagulants \u00e0 prise orale - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"DPd3Su8ZZt\"><a href=\"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-4\/\">Progr\u00e8s de la mise au point d\u2019un agent neutralisant les effets des nouveaux anticoagulants \u00e0 prise orale<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/fr\/2014\/11\/24\/congres-scientifique-de-lamerican-heart-associat-4\/embed\/#?secret=DPd3Su8ZZt\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Progr\u00e8s de la mise au point d\u2019un agent neutralisant les effets des nouveaux anticoagulants \u00e0 prise orale\u00a0\u00bb &#8212; The Medical Xchange\" data-secret=\"DPd3Su8ZZt\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/11\/EX_7010_AHA_ANNEXA_A_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Chicago \u2013 Des chercheurs ont rapport\u00e9 qu\u2019un agent neutralisant dirig\u00e9 contre un nouvel anticoagulant \u00e0 prise orale aurait pratiquement normalis\u00e9 tous les param\u00e8tres de la coagulation au cours d\u2019une \u00e9tude men\u00e9e chez des adultes d\u2019\u00e2ge m\u00fbr en sant\u00e9, et ce sans aucun signe de la formation d\u2019anticorps, ce qui confirmerait les r\u00e9sultats d\u2019\u00e9tudes de validation de principe r\u00e9alis\u00e9es ant\u00e9rieurement. Ces donn\u00e9es de Phase III rendent compte de la neutralisation rapide de l\u2019activit\u00e9 anticoagulante de l\u2019apixaban par l\u2019andexanet alpha."}